Last reviewed · How we verify

AXICABTAGENE CILOLEUCEL — Competitive Intelligence Brief

AXICABTAGENE CILOLEUCEL (AXICABTAGENE CILOLEUCEL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD19-directed Chimeric Antigen Receptor [EPC].

marketed CD19-directed Chimeric Antigen Receptor [EPC] Gene therapy Live · refreshed every 30 min

Target snapshot

AXICABTAGENE CILOLEUCEL (AXICABTAGENE CILOLEUCEL).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AXICABTAGENE CILOLEUCEL TARGET AXICABTAGENE CILOLEUCEL marketed CD19-directed Chimeric Antigen Receptor [EPC] 2018-01-01
Kymriah TISAGENLECLEUCEL Novartis Pharmaceuticals Corporation marketed CD19-directed Chimeric Antigen Receptor [EPC] 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD19-directed Chimeric Antigen Receptor [EPC] class)

  1. · 1 drug in this class
  2. Novartis Pharmaceuticals Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AXICABTAGENE CILOLEUCEL — Competitive Intelligence Brief. https://druglandscape.com/ci/axicabtagene-ciloleucel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: